Optmed Inc. Receives Clearance From The U.S. Food & Drug Administration (FDA) For Its 510(K) Tearrepairtm Liquid Skin Protectant

10/16/2024 9:15:45 AM

(MENAFN- PR Newswire) NEW YORK, Oct. 16, 2024 /PRNewswire/ -- OptMed, Inc. proudly announces it has received a letter from the S & Drug Administration (FDA) clearing its 510(k) TearRepairTM Liquid Skin Protectant.

TearRepairTM Liquid Skin Protectant is a non-cytotoxic, methylidene malonate based, rapid-drying liquid barrier film for the protection of the skin. It is applied as a liquid and dries within minutes, adhering to the contours of the skin to form a transparent flexible film. TearRepairTM will wear off naturally and is provided sterile.

Ervin Braun, OptMed CEO commented, "This is a significant and
important milestone for our company. OptMed will aggressively move forward to commercialize TearRepairTM. Braun added, "OptMed's proprietary methylidene malonate platform technology provides the company flexibility to further develop new product options to protect skin as well as address acute,
surgical, and chronic wounds like lacerations, incisions, open wounds, and
potentially
internal applications."

Optmed, Inc. has been developing a completely new and revolutionary medical adhesive for over 10 years, whose chemistry,
methylidene malonate,
is unlike any other chemistry offered to the market and indeed may be integral to revolutionizing surgical procedures in the future.

OptMed, Inc. is a privately held medical device company that is engaged in the development,
manufacturing, and commercialization of methylidene
malonate-based products. With this FDA clearance, Optmed now can offer a line of skin protectants and topical surgical adhesives. While this is a significant milestone for the company, Optmed's future steps include pursuing the internal
surgical adhesive market with its proprietary polymer chemistry.

For more information contact:
Ervin Braun
CEO - OptMed
M:(203) 273-7450
E-Mail: [email protected]

SOURCE Optmed, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN16102024003732001241ID1108786841

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.